TPCW
SNDX icon

TD Private Client Wealth’s Syndax Pharmaceuticals SNDX Stock Holding History

TD Private Client Wealth’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-54
Closed -$506 – 1564
2025
Q2 		$506 Buy
+54
New +$594 ﹤0.01% 1346

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

TD Private Client Wealth's SNDX Position: Q3 2025 in Review

TD Private Client Wealth sold out of Syndax Pharmaceuticals (SNDX) in Q3 2025, closing a stake of 54 shares — an estimated $506 sold.

TD Private Client Wealth first reported a position in SNDX in Q2 2025 and held it in 1 quarter. The position peaked at $506 in Q2 2025. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

  • TD Private Client Wealth reported no remaining Syndax Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • TD Private Client Wealth sold 54 Syndax Pharmaceuticals shares in Q3 2025, an estimated $506.
  • TD Private Client Wealth first reported a position in Syndax Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • TD Private Client Wealth's Syndax Pharmaceuticals position peaked at $506 in Q2 2025.
  • 227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on TD Private Client Wealth's 13F filing for Q3 2025, filed 27 Oct 2025.